Urs A Ochsner

Summary

Publications

  1. doi request reprint Inhibitory effect of REP3123 on toxin and spore formation in Clostridium difficile, and in vivo efficacy in a hamster gastrointestinal infection model
    Urs A Ochsner
    Replidyne, Inc, Louisville, CO 80027, USA
    J Antimicrob Chemother 63:964-71. 2009
  2. doi request reprint Spectrum of activity and mode of action of REP3123, a new antibiotic to treat Clostridium difficile infections
    Ian A Critchley
    Replidyne, Inc, Louisville, CO 80027, USA
    J Antimicrob Chemother 63:954-63. 2009
  3. pmc Inhibition of methionyl-tRNA synthetase by REP8839 and effects of resistance mutations on enzyme activity
    Louis S Green
    Replidyne, Inc, Louisville, CO 80027, USA
    Antimicrob Agents Chemother 53:86-94. 2009
  4. pmc Mode of action and biochemical characterization of REP8839, a novel inhibitor of methionyl-tRNA synthetase
    Urs A Ochsner
    Replidyne, Inc, Louisville, Colorado 80027, USA
    Antimicrob Agents Chemother 49:4253-62. 2005
  5. pmc Transient loss of high-level mupirocin resistance in Staphylococcus aureus due to MupA polymorphism
    Daniel G Driscoll
    Replidyne, Inc, Dept Microbiology, 1450 Infinite Dr, Louisville, CO 80027, USA
    Antimicrob Agents Chemother 51:2247-8. 2007
  6. doi request reprint Recent advances in the preclinical evaluation of the topical antibacterial agent REP8839
    Ian A Critchley
    Microbiology Research, Replidyne, Inc, 1450 Infinite Drive, Louisville, CO 80027, USA
    Curr Opin Chem Biol 12:409-17. 2008
  7. doi request reprint Detection of Clostridium difficile toxins A, B and binary toxin with slow off-rate modified aptamers
    Urs A Ochsner
    SomaLogic, Inc, 2945 Wilderness Place, Boulder, CO 80301, USA
    Diagn Microbiol Infect Dis 76:278-85. 2013
  8. ncbi request reprint Aminoacyl-tRNA synthetases: essential and still promising targets for new anti-infective agents
    Urs A Ochsner
    Replidyne, Inc, 1450 Infinite Dr, Louisville, CO 80027, USA
    Expert Opin Investig Drugs 16:573-93. 2007
  9. pmc Development of 4H-pyridopyrimidines: a class of selective bacterial protein synthesis inhibitors
    Joseph W Guiles
    Replidyne, Inc, Louisville, CO, USA
    Org Med Chem Lett 2:5. 2012
  10. pmc Antibacterial activity of REP8839, a new antibiotic for topical use
    Ian A Critchley
    Replidyne, Inc, Louisville, CO 80027, USA
    Antimicrob Agents Chemother 49:4247-52. 2005

Collaborators

Detail Information

Publications11

  1. doi request reprint Inhibitory effect of REP3123 on toxin and spore formation in Clostridium difficile, and in vivo efficacy in a hamster gastrointestinal infection model
    Urs A Ochsner
    Replidyne, Inc, Louisville, CO 80027, USA
    J Antimicrob Chemother 63:964-71. 2009
    ..This novel agent was investigated for its ability to block the production of toxins and spores, and was tested for efficacy in vivo in a hamster model...
  2. doi request reprint Spectrum of activity and mode of action of REP3123, a new antibiotic to treat Clostridium difficile infections
    Ian A Critchley
    Replidyne, Inc, Louisville, CO 80027, USA
    J Antimicrob Chemother 63:954-63. 2009
    ..The aim of this study was to characterize the antimicrobial profile of REP3123, a novel inhibitor of methionyl-tRNA synthetase (MetRS) in development for the treatment of Clostridium difficile infection...
  3. pmc Inhibition of methionyl-tRNA synthetase by REP8839 and effects of resistance mutations on enzyme activity
    Louis S Green
    Replidyne, Inc, Louisville, CO 80027, USA
    Antimicrob Agents Chemother 53:86-94. 2009
    ..These observations provide a potential mechanistic explanation for the reduced growth fitness observed with MetRS mutant strains relative to that with wild-type Staphylococcus aureus...
  4. pmc Mode of action and biochemical characterization of REP8839, a novel inhibitor of methionyl-tRNA synthetase
    Urs A Ochsner
    Replidyne, Inc, Louisville, Colorado 80027, USA
    Antimicrob Agents Chemother 49:4253-62. 2005
    ..In conclusion, we demonstrate by biochemical, physiologic, and genetic mode-of-action studies that REP8839 exerts its antibacterial activity through specific inhibition of MetS, a novel target...
  5. pmc Transient loss of high-level mupirocin resistance in Staphylococcus aureus due to MupA polymorphism
    Daniel G Driscoll
    Replidyne, Inc, Dept Microbiology, 1450 Infinite Dr, Louisville, CO 80027, USA
    Antimicrob Agents Chemother 51:2247-8. 2007
    ..Reversion to the wild-type allele and restoration of high-level resistance occurred with high frequency (>10(-6)), indicating the transient nature of MupA polymorphism...
  6. doi request reprint Recent advances in the preclinical evaluation of the topical antibacterial agent REP8839
    Ian A Critchley
    Microbiology Research, Replidyne, Inc, 1450 Infinite Drive, Louisville, CO 80027, USA
    Curr Opin Chem Biol 12:409-17. 2008
    ..aureus and can be formulated at high concentrations to minimize the development of resistance. A formulation of REP8839 has demonstrated efficacy in a porcine partial thickness wound infection model against mupirocin-resistant S. aureus...
  7. doi request reprint Detection of Clostridium difficile toxins A, B and binary toxin with slow off-rate modified aptamers
    Urs A Ochsner
    SomaLogic, Inc, 2945 Wilderness Place, Boulder, CO 80301, USA
    Diagn Microbiol Infect Dis 76:278-85. 2013
    ..SOMAmers detected toxins A, B and binary toxin in culture supernatants from toxigenic C. difficile, including a BI/NAP1 strain and historic strains...
  8. ncbi request reprint Aminoacyl-tRNA synthetases: essential and still promising targets for new anti-infective agents
    Urs A Ochsner
    Replidyne, Inc, 1450 Infinite Dr, Louisville, CO 80027, USA
    Expert Opin Investig Drugs 16:573-93. 2007
    ..This review provides an update on the present strategies to develop novel aaRS inhibitors as anti-infective drugs...
  9. pmc Development of 4H-pyridopyrimidines: a class of selective bacterial protein synthesis inhibitors
    Joseph W Guiles
    Replidyne, Inc, Louisville, CO, USA
    Org Med Chem Lett 2:5. 2012
    ..abstract:..
  10. pmc Antibacterial activity of REP8839, a new antibiotic for topical use
    Ian A Critchley
    Replidyne, Inc, Louisville, CO 80027, USA
    Antimicrob Agents Chemother 49:4247-52. 2005
    ..aureus highlights the need for a new topical antibiotic with the ability to inhibit high-level mupirocin-resistant strains and other emerging phenotypes, such as vancomycin-resistant and community-acquired methicillin-resistant isolates...
  11. pmc Elucidating novel serum biomarkers associated with pulmonary tuberculosis treatment
    Mary A De Groote
    SomaLogic, Inc, Boulder, Colorado, USA
    PLoS ONE 8:e61002. 2013
    ..The novel proteins elucidated in this work may provide new insights for understanding TB disease, its treatment and subsequent healing processes that occur in response to effective therapy...